Anton
Дело отдельно взятого человека на мой взгляд. Человек уже решил, что вакцинироваться не хочет, собственно приняв это решение он всеми правдами-неправдами будет искать причины для медотвода. Всех благ такому человеку, его родным и близким в эти времена
Станислав Константинович
Здравствуйте. Является ли Болезнь Крона (операция была в 2001 году) медотводом от вакцинации? Спасибо.
Не является
https://rheumatolog.su/news/o-vakcinacii-protiv-sOVID-19-pri-immunovospalitelnyh-revmaticheskih-zabolevaniyah/
2. В случае, если пациент с ИВРЗ уже получает терапию иммуносупрессивными препаратами, при проведении вакцинации против COVID-19 с целью повышения иммуногенности вакцины возможны следующие действия [1]:
метотрексат, ингибиторы Янус-киназ, циклофосфан, микофенолата мофетил – пропустить применение препарата в течение 1 недели после каждой дозы вакцины, если это возможно;
абатацепт п/к – пропустить применение препарата в течение 1 недели до и 1 недели после первой дозы вакцины, 2-я доза – без изменений;
абатацепт в/в – пропустить применение препарата в течение 4 недель до и 1 недели после первой дозы вакцины, 2-я доза – без изменений
ритуксимаб - начать вакцинацию, как минимум, через 5 мес. от момента последнего введения препарата и за 4 недели до предстоящей инфузии.
Вот конкретно и по пунктам. Все. Точка
По твоей теме вот https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834976/ но кароче лучше сделать чем не делать
High-dose systemic corticosteroids, particularly in combination with other immunosuppressants, may reduce vaccine immunogenicity, as has been observed with annual influenza vaccination.25 When possible, SARS-CoV-2 vaccination should be administered while patients are taking the lowest dose of systemic corticosteroid. These considerations should be interpreted in the context of individual cases and discussed with patients.
Рекомендации британцев
https://www.bsg.org.uk/covid-19-advice/british-society-of-gastroenterology-inflammatory-bowel-disease-section-and-ibd-clinical-research-group-position-statement-on-sars-cov2-vaccination/
Anton
Glomerular disease following COVID-19 vaccination
Efforts to vaccinate the world's population against SARS-CoV-2 are underway and include the messenger RNA (mRNA) vaccines (Moderna mRNA-1273 and Pfizer-BioNTech BNT162b2). Emerging data, currently limited to case reports, suggest that de novo glomerular disease and relapse of pre-existing glomerular disease have occurred shortly after administration of the Pfizer and Moderna vaccines [1-13]. However, these events are overall rare, and a causal link with the COVID-19 vaccines is not established. Thus, we strongly encourage COVID-19 vaccination among patients with pre-existing glomerular disease, even if they are on immunosuppressive therapy. For patients who develop glomerular disease after the first dose of a mRNA vaccine, we advise a discussion of risk and benefits of further vaccination based upon the individual’s type and severity of glomerular disease and whether or not they are in remission by the time of the scheduled second dose.
See 'COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension', section on 'COVID-19 vaccine-associated glomerular disease' and 'COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension', section on 'COVID-19 vaccination in patients with glomerular disease'.
1. Anderegg MA, Liu M, Saganas C, et al. De novo vasculitis after mRNA-1273 (Moderna) vaccination. Kidney Int 2021.
2. Tan HZ, Tan RY, Jun Choo JC, et al. Is COVID-19 vaccination unmasking glomerulonephritis? Kidney Int 2021.
3. Lebedev L, Sapojnikov M, Wechsler A, et al. Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine. Am J Kidney Dis 2021.
4. Maas RJ, Gianotten S, van der Meijden WAG. An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine. Am J Kidney Dis 2021.
5. D'Agati VD, Kudose S, Bomback AS, et al. Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine. Kidney Int 2021.
6. Holzworth A, Couchot P, Cruz-Knight W, Brucculeri M. Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine. Kidney Int 2021.
7. Perrin P, Bassand X, Benotmane I, Bouvier N. Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy. Kidney Int 2021.
8. Negrea L, Rovin BH. Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy. Kidney Int 2021; 99:1487.
9. Rahim SEG, Lin JT, Wang JC. A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination. Kidney Int 2021.
10. Komaba H, Wada T, Fukagawa M. Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine. Am J Kidney Dis 2021.
11. Kervella D, Jacquemont L, Chapelet-Debout A, et al. Minimal change disease relapse following SARS-CoV-2 mRNA vaccine. Kidney Int 2021.
12. Schwotzer N, Kissling S, Fakhouri F. Letter regarding "Minimal change disease relapse following SARS-CoV-2 mRNA vaccine". Kidney Int 2021.
13. Aydin MF, Yildiz A, Oruc A, et al. Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination. Kidney Int 2021.